Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Krogsgaard

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Ugeskrift for Laeger|February 8, 2002
[Screening for hepatitis B]Kim Krogsgaard
Ugeskrift for Laeger|July 2, 2003
[Needlestick injuries among health personnel]Kim Krogsgaard
Ugeskrift for Laeger|May 22, 2003
[Administrative organization and responsibility]Jannik C Hilsted, Kim Krogsgaard
Ugeskrift for Laeger|May 22, 2003
[How to establish GCP-units in Denmark?]Kim Krogsgaard, Per Buch Andreasen
Ugeskrift for Laeger|January 30, 2003
[Hepatitis B--a viral oncogene?]Nina M Weis, Kim Krogsgaard
Ugeskrift for Laeger|March 31, 2004
[Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin]Ulla Bjerre Christensen, Kim Krogsgaard
Ugeskrift for Laeger|April 19, 2003
[Treatment and prevention of hepatitis C--progress and challenges. The Danish Society of Hepatology]Jens Bukh, Erik Christensen, Kim Krogsgaard
Ugeskrift for Laeger|January 31, 2002
[Polyarteritis nodosa and hepatitis B infection treated with lamivudine]Tine Münster, Nina M Weis, Kim Krogsgaard
Journal of Gastroenterology and Hepatology|October 13, 2007
Demonstration of an association between detection of IgG antibody reactivity towards the C-terminal region of the preS1 protein of hepatitis B virus and the capacity to respond to interferon therapy in chronic hepatitis BUlla Hellström, Magnus Lindh, Kim Krogsgaard, et al.
Journal of Medical Virology|January 10, 2002
Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis BCharles Hannoun, Peter Horal, Kim Krogsgaard, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Ugeskrift for Laeger|February 8, 2002
[Screening for hepatitis B]Kim Krogsgaard
Ugeskrift for Laeger|July 2, 2003
[Needlestick injuries among health personnel]Kim Krogsgaard
Ugeskrift for Laeger|May 22, 2003
[Administrative organization and responsibility]Jannik C Hilsted, Kim Krogsgaard
Ugeskrift for Laeger|May 22, 2003
[How to establish GCP-units in Denmark?]Kim Krogsgaard, Per Buch Andreasen
Ugeskrift for Laeger|January 30, 2003
[Hepatitis B--a viral oncogene?]Nina M Weis, Kim Krogsgaard
Ugeskrift for Laeger|March 31, 2004
[Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin]Ulla Bjerre Christensen, Kim Krogsgaard
Ugeskrift for Laeger|April 19, 2003
[Treatment and prevention of hepatitis C--progress and challenges. The Danish Society of Hepatology]Jens Bukh, Erik Christensen, Kim Krogsgaard
Ugeskrift for Laeger|January 31, 2002
[Polyarteritis nodosa and hepatitis B infection treated with lamivudine]Tine Münster, Nina M Weis, Kim Krogsgaard
Journal of Gastroenterology and Hepatology|October 13, 2007
Demonstration of an association between detection of IgG antibody reactivity towards the C-terminal region of the preS1 protein of hepatitis B virus and the capacity to respond to interferon therapy in chronic hepatitis BUlla Hellström, Magnus Lindh, Kim Krogsgaard, et al.
Journal of Medical Virology|January 10, 2002
Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis BCharles Hannoun, Peter Horal, Kim Krogsgaard, et al.
Pageof 3